Gland Pharma Limited reported its Q3 financial results for the quarter ended December 31, 2024, showcasing stable growth despite minor sequential revenue contractions. The company reported a net profit of ₹204.62 crore, an 11.8% increase compared to ₹183.18 crore in the corresponding quarter of the previous year.
Quarterly Financial Highlights:
- Revenue from Operations: ₹1,384.05 crore, compared to ₹1,405.83 crore in the previous quarter and ₹1,545.15 crore YoY.
- Total Income: ₹1,442.54 crore compared to ₹1,465.49 crore QoQ and ₹1,582.57 crore YoY.
- Profit Before Tax: ₹299.30 crore compared to ₹256.78 crore in the previous quarter and ₹283.13 crore YoY.
Key Metrics:
- Cost of Materials Consumed: ₹437.38 crore, reflecting reduced raw material consumption compared to the previous quarter.
- Total Expenses: ₹1,143.27 crore, down from ₹1,208.71 crore in the prior quarter, showcasing cost optimization.
- Employee Benefits Expense: ₹342.86 crore compared to ₹329.81 crore QoQ, indicating slight increments.
Nine-Month Performance:
- Total Revenue: ₹4,361.17 crore, marginally higher than ₹4,255.30 crore YoY.
- Net Profit: ₹511.99 crore, up from ₹580.04 crore YoY due to efficient operational management.
Gland Pharma remains confident about future growth, driven by domestic and international demand for its product portfolio. The company’s ongoing investments in R&D and capacity expansion are expected to fuel long-term growth.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions.
